Reuters -- BioCryst Pharmaceuticals Inc said it is preparing to deliver a portion of its finished flu product peramivir, sufficient to treat about 1,000 patients, for addition to the U.S. Centers for Disease Control and Prevention Strategic National Stockpile.
